These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 34584238)
1. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Liang EC; Chen C; Lu R; Mannis GN; Muffly L Bone Marrow Transplant; 2021 Dec; 56(12):3091-3093. PubMed ID: 34584238 [TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
3. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia. Dillon LW; Gui G; Ravindra N; Andrew G; Mukherjee D; Wong ZC; Huang Y; Gerhold J; Holman M; D'Angelo J; Miller J; Higgins J; Salk JJ; Auletta JJ; El Chaer F; Devine SM; Jimenez-Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Spellman SR; Zeger SL; Page KM; Hourigan CS JAMA Oncol; 2024 Aug; 10(8):1104-1110. PubMed ID: 38696205 [TBL] [Abstract][Full Text] [Related]
4. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB; J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171 [TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553 [TBL] [Abstract][Full Text] [Related]
8. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. Helbig G; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kopińska A; Boral K; Grygoruk-Wiśniowska I; Stachowicz M; Karolczyk A Ann Hematol; 2020 Aug; 99(8):1845-1853. PubMed ID: 32333156 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446 [TBL] [Abstract][Full Text] [Related]
10. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660 [TBL] [Abstract][Full Text] [Related]
11. Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML. Wan L; Ding S; Xu M; Lv K; Du Y; Wu D; Xu M; Liu Y Int J Hematol; 2022 Nov; 116(5):731-743. PubMed ID: 35857193 [TBL] [Abstract][Full Text] [Related]
12. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760 [TBL] [Abstract][Full Text] [Related]
13. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Grunwald MR; Tseng LH; Lin MT; Pratz KW; Eshleman JR; Levis MJ; Gocke CD Biol Blood Marrow Transplant; 2014 Dec; 20(12):1989-95. PubMed ID: 25240816 [TBL] [Abstract][Full Text] [Related]
14. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy for Burchert A Haematologica; 2021 Mar; 106(3):664-670. PubMed ID: 33472354 [TBL] [Abstract][Full Text] [Related]
17. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis. Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341 [TBL] [Abstract][Full Text] [Related]
18. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627 [TBL] [Abstract][Full Text] [Related]
19. Lee JM; Park S; Hwang I; Kang D; Cho BS; Kim HJ; Ahn A; Kim M; Kim Y Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551616 [TBL] [Abstract][Full Text] [Related]
20. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]